{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ren W"],"funding":["CCR NIH HHS","National Cancer Institute","NCI NIH HHS","National Institutes of Health","Cancer Prevention and Research Institute of Texas"],"pagination":["117400"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10848874"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["92"],"pubmed_abstract":["The oxetane functional group offers a variety of potential advantages when incorporated within appropriate therapeutic agents as a ketone surrogate. OXi8006, a 2-aryl-3-aroyl-indole analogue, functions as a small-molecule inhibitor of tubulin polymerization that has a dual mechanism of action as both an antiproliferative agent and a tumor-selective vascular disrupting agent. Replacement of the bridging ketone moiety in OXi8006 with an oxetane functional group has expanded structure activity relationship (SAR) knowledge and provided insights regarding oxetane incorporation within this class of molecules. A new synthetic method using an oxetane-containing tertiary alcohol subjected to Lewis acid catalyzed conditions led to successful Friedel-Crafts alkylation and yielded fourteen new oxetane-containing indole-based molecules. This synthetic approach represents the first method to successfully install an oxetane ring at the 3-position of a 2-aryl-indole system. Several analogues showed potent cytotoxicity (micromolar GI<sub>50</sub> values) against human breast cancer cell lines (MCF-7 and MDA-MB-231) and a pancreatic cancer cell line (PANC-1), although they proved to be ineffective as inhibitors of tubulin polymerization. Molecular docking studies comparing colchicine with the OXi8006-oxetane analogue 5m provided a rationale for the differential interaction of these molecules with the colchicine site on the tubulin heterodimer."],"journal":["Bioorganic & medicinal chemistry"],"pubmed_title":["Structure Guided Design, Synthesis, and Biological Evaluation of Oxetane-Containing Indole Analogues."],"pmcid":["PMC10848874"],"funding_grant_id":["R01 CA244579","HHSN261200800001E","HHSN261200800001C","RP200614","R01 CA238624","R01CA238624","R01CA244579"],"pubmed_authors":["Ren W","Bai R","Francis R","VanNatta J","Ward JD","Tankoano PE","Hamel E","Pinney KG","Trawick ML","Vairin R","Deng Y"],"additional_accession":[]},"is_claimable":false,"name":"Structure Guided Design, Synthesis, and Biological Evaluation of Oxetane-Containing Indole Analogues.","description":"The oxetane functional group offers a variety of potential advantages when incorporated within appropriate therapeutic agents as a ketone surrogate. OXi8006, a 2-aryl-3-aroyl-indole analogue, functions as a small-molecule inhibitor of tubulin polymerization that has a dual mechanism of action as both an antiproliferative agent and a tumor-selective vascular disrupting agent. Replacement of the bridging ketone moiety in OXi8006 with an oxetane functional group has expanded structure activity relationship (SAR) knowledge and provided insights regarding oxetane incorporation within this class of molecules. A new synthetic method using an oxetane-containing tertiary alcohol subjected to Lewis acid catalyzed conditions led to successful Friedel-Crafts alkylation and yielded fourteen new oxetane-containing indole-based molecules. This synthetic approach represents the first method to successfully install an oxetane ring at the 3-position of a 2-aryl-indole system. Several analogues showed potent cytotoxicity (micromolar GI<sub>50</sub> values) against human breast cancer cell lines (MCF-7 and MDA-MB-231) and a pancreatic cancer cell line (PANC-1), although they proved to be ineffective as inhibitors of tubulin polymerization. Molecular docking studies comparing colchicine with the OXi8006-oxetane analogue 5m provided a rationale for the differential interaction of these molecules with the colchicine site on the tubulin heterodimer.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Sep","modification":"2026-06-02T22:57:34.095Z","creation":"2025-04-04T19:39:28.662Z"},"accession":"S-EPMC10848874","cross_references":{"pubmed":["37556912"],"doi":["10.1016/j.bmc.2023.117400"]}}